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We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-
incubation with efalizumab concentrations similar to those reached during in vivo therapy almost
completely saturated COlla binding sites without affecting the membrane expression of COllb,
C0128a or C0128b. There was a significant reduction in the chemotactic activity ofthe pre-treated cells
toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen
radicals remained unchanged. One month after the administration of efalizumab to five patients with
psoriasis (Tl) circulating neutrophil counts increased by 34% from pre-therapy (TO) with no change
in the number of monocytes. In the same patients the COlla binding sites on phagocytes were >90%
saturated, and there was also a significant down-modulation on neutrophils (44% of TO) and monocytes
(63% of TO). In line with in vitro results, efalizumab treatment caused a significant deficiency in the
chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst,
production of pro-inflammatory cytokines or the membrane expression ofCOllb, C0l28a and C0128b.
Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity
in patients with psoriasis.
Psoriasis is a chronic, immune-mediated inflam-
matory disease of the dermis and epidermis that is
characterized by an abundance of T cells, increased
vascularity and high concentrations oftumour necro-
sis factor-a (TNF-a) in skin lesions (1). As most of
the currently available phototherapies and systemic
treatments (i.e. methotrexate and cyclosporin) for
moderate-to-severe psoriasis are ineffective in some
patients, and have potentially serious side-effects in
others that complicate long-term disease manage-
ment (2), various treatments with improved safety
profiles have been proposed.
Better knowledge of the pathogenesis of the
disease has suggested some immunological targets
such as 'l-Iymphocytes and inflammatory cytokines
(3), and a number of biological agents have been
approved by the US Food and Drug Administra-
tion for moderate-to-severe plaque psoriasis. These
include alefacept, a fully human recombinant leu-
kocyte function-associated antigen-3 (LFA-3)/IgG I
fusion protein that inhibits T cell activation and
selectively reduces memory T cells (4); infliximab
and etanercept, which are TNF-a antagonists (5-6);
and efalizumab, a humanized monoclonal antibody
(mAb) that binds to the alpha subunit (COlla) of
LFA-I, and inhibits the homing and activation ofT
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cells (7).
The efficacy and safety of efalizumab have been
demonstrated in many clinical trials (7-9), and the
results of the European experience with efalizumab
in routine clinical practice have recently been pub-
lished (10). Its mechanism ofaction is clearly related
to its inhibition of the activation, adhesion and traf-
ficking of T cells (7), but it may also bind to other
LFA-I positive cells such as neutrophils and mono-
cytes (11), which play an important role in maintain-
ing and amplifying T cell-associated inflammation in
psoriatic plaques (12-13).
To the best of our knowledge, there are no pub-
lished data concerning the effect of efalizumab on
phagocytic cell function. We therefore evaluated
certain phenotypical and functional aspects of neu-
trophils and monocytes after their in vitro pre-incu-
bation with different mAb concentrations, and then
repeated the same evaluations using phagocytic cells
obtained from psoriatic patients before and after
treatment with efalizumab for 1 month. Chemotaxis,
phagocytosis, and the production of reactive oxygen
intermediates (ROI) and inflammatory cytokines
were assessed in peripheral blood neutrophils and
monocytes, as was the membrane expression of
CD II a, CD 11 b (the alpha subunit of complement
receptor type 3), CDI28a1CXCRl and CD128b/
CXCR2, the main interleukin-S (IL-8) receptors on
phagocytes.
MATERIALS AND METHODS
In vitro study
The effect of efalizumab activity on phagocytic cell
functions was evaluated in vitro using peripheral blood
neutrophils and monocytes obtained from five healthy
volunteers. The purified cells (see below) were incubated
with different drug concentrations (see Figures and Ta-
bles) for 30 minutes at 4°C, washed and immediately used
in the assays; the final concentrations used in vitro were
similar to those obtained in vivo at steady-state after four
weekly doses of efalizumab (I mg/kg/week) (II).
Ex vivo study
Peripheral blood samples were collected from five
selected patients (four men and one woman; mean age 42
years, range 30-45 years) with active psoriasis (Psoriasis
Area and Severity Index score> I0) (14). All of the pa-
tients had failed to respond to, were intolerant of, or had
contraindications against at least two systemic therapies,
including methotrexate, cyclosporin A, acitretine and
psoralen combined with ultraviolet light A, and all gave
their written informed consent to participate in the study.
The controls were ten healthy age- and gender-matched
individuals.
Efalizumab was administered subcutaneously every
week. After a first conditioning dose of 0.7 mg/kg, the
drug was administered at a dose of I mg/kg. Peripheral
blood samples were obtained before treatment (TO) and I
month after the start of treatment (T I).
Peripheral blood neutrophils were obtained by means
of density gradient centrifugation (Lymphoprep; Nye-
gaard, Oslo, Norway) (15). The purified cells consisted of
a population of>95% pure, viable neutrophils, as assessed
on the basis of morphology and trypan blue exclusion.
Peripheral blood monocytes were purified on a Nycoprep
1.068 gradient (Axis-Shield; Oslo, Norway) as described
in detail by Boyum (16), which routinely yielded 85-90%
monocytes as assessed by Wright staining, non-specific
esterase staining and, in some cases, immunofluorescent
staining for CD14; viability was >95% by trypan blue
exclusion.
Neutrophil and monocyte chemotaxis were evalu-
ated using a modified Boyden chamber assay with blind
well chambers and 3 11m (for neutrophils) or 5 11m (for
monocytes) micropore filters (Millipore; Bedford, MA,
USA) (17). The chemotactic response was determined
by evaluating the number of cells per high power field
(hpt) that had migrated through the entire thickness of
the filter. The chemo-attractants were zymosan-activated
serum (ZAS) as a source ofC5a (I mg zymosan/ml serum
for 30 minutes at 37°C) at a 1% (vol/vol) final dilution in
RPMI 1640 (HyClone Laboratories, Logan, UT, USA);
the synthetic peptide N-formyl-methionyl-Ieucyl-pheny-
lalanine (FMLP; Sigma) at a final concentration of l O:"
M; and IL-8 (Biosource, Camarillo, CA, USA) at a final
concentration of 100 ng/ml.
Phagocytosis was evaluated using C3-coated zymosan
(C3Zy) as particles for uptake (18). The number of parti-
cles ingested per cell (phagocytic index) was established
by means of direct light microscopy (xlOOO magnifica-
tion) on at least 200 cells.
Lucigenin (bis-N-methylacridinum nitrate; Sigma)-
amplified chemiluminescence (CL) was used to evaluate
the phagocyte production of ROI (19). A Luminometer
1251 (LKB, Wallac, Turku, Finland) was used to record
the background of the light output (in mV) before to the
addition of the stimuli: phorbol 12-myristate 13-acetate
(PMA; final concentration 5 ng/ml; Sigma) or FMLP (10-7
M final concentration) The background counts were sub-
tracted from the values obtained after neutrophil stimula-
tion.
Flow cytometry of purified phagocytes (in vitro ex-
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Table I. Effect ofefalizumab in vitro on the production ofchemiluminescence (CL) and on the phagocytic capacity of
neutrophils and monocytes.
Efalizumab (ug/ml)
Test 0 1 10 100
PMA-stimulated CLa
Neutrophils 48.7 ± 0.4 42.9 ± 2.1 40.9 ± 2.1 40.4 ± 2.4
Monocytes 12.2± 1.6 12.0±2.3 10.5± 1.4 11.3± 1.5
FMLP-stimulated CLa
Neutrophils 19.2± 0.3 18.0± 0.3 18.0± 0.4 20.2 ± 0.4
Monocytes 2.2 ± 0.3 1.8 ± 0.3 2.1 ± 0.5 2.7 ± 0.5
Phagocytosis"
Neutrophils 1.03 ± 0.03 0.94 ± 0.13 1.00± 0.16 1.07± 0.05
Monocytes 1.19± 0.03 1.20± 0.06 1.23± 0.03 1.19± 0.08
..
"Peak CL values in mV; "Phagocytic index
FMLp, N-formyl-methionyl-leucyl-phenylalanine; PMA, phorbol J2-myristate J3-acetate
The cells were preincubated with different concentrations ofefalizumab before being testedfor chemiluminescence and
phagocytosis. Results are means ± standard error ofthree separate experiments.
periments) (18) or whole blood samples (ex vivo studies)
(20) was used to determine the membrane expression of
CD IIb, CD 128a and CD 128b; specific fluorescent-con-
jugated mAbs (Becton Dickinson, San Jose, CA, USA)
were used in these assays. Neutrophil and monocyte
COila expression was determined by FACS using two
fluorescence-labelled anti-COila antibody clones: clone
MHM24 (Dako Corporation, Carpinteria, CA, USA) binds
to an epitope similar to that used by efalizumab and there-
fore only to free CD IIa (i.e. not bound by efalizumab)
(11), whereas clone HIlll (Becton Dickinson) binds to a
different CD II a epitope remote from the efalizumab bind-
ing site, and therefore binds to all of the CD II a on a cell
regardless of whether or not it is also bound by efalizu-
mab (II). The neutrophil and monocyte populations were
identified on the basis of their forward- and side-scatter
characteristics. A relative measure of antigen expression
was obtained using mean fluorescence intensity (MFI),
converted from a log to a linear scale, after subtracting
the cells' self-fluorescence and the fluorescence of cells
incubated with irrelevant isotype control mAbs.
Production ofcytokines in vitro
The spontaneous and lipopolysaccharide (LPS)-in-
duced production ofTNF-a, ILl-~ and IL-8 by leukocytes
was evaluated on whole blood samples (21) obtained from
the controls and from patients with psoriasis at TOand Tl.
The samples (100 Ill, diluted 1/10) were incubated at 37°C
for 18 hours in humidified atmosphere (5% CO,) with or
without LPS from Escherichia coli 055:B5, (S-igma) 10
ng/ml and the cytokine levels were determined in cell-free
supernatants using a specific ELISA (Biotrak, Amersham,
UK).
Statistical analysis
The data are expressed as mean values ± standard
error of the mean (SE), and were statistically analysed
using Student's t test for unpaired or paired data as ap-
propriate. A p value of <0.05 was considered statistically
significant.
RESULTS
In vitro study
As shown in Fig. l A, pre-incubation of the neu-
trophils and monocytes with efalizumab led to dose-
dependent saturation of the CDII a binding sites, as
440 F. CAPSONI ET AL.
Table II. Leukocyte and leukocyte subpopulations (cells/ul), chemiluminescence (CL), phagocytosis andcytokine production
by controls andpatients with psoriasis before treatment (TO) and after treatment with efalizumab for 1 month (Tl).
Controls Patients Patients
(TO) (Tl)
WBC 6170 5740 7700
(range) (4000-9000) (4200-6900) (6200-8900)
Lymphocytes 2000 1650 2650
(range) (\ 400-2800) (990-2300) (2100-3600)
Neutrophils 3380 3450 4000
(range) (2300--4500) (2300-3900) (3200-5000)
Monocytes 526 600 610
(range) (330-780) (480-820) (470-750)
PMA-stimulated CLa (mean
±SE)
Neutrophils 50.2 ± 6.0 57.7 ± 10.7 50.6 ± 2.64
Monocytes 10.9 ± 0.8 11.9 ± 1.7 10.3 ± 0.9
FMLP-stimulated CLa
(mean ± SE)
Neutrophils 18.8 ± 3.6 27.7 ± 3.4 17.5 ± 1.9
Monocytes 2.5 ± 0.4 2.7 ±O.I 2.7 ± 0.2
Phagocytosis" (mean ± SE)
Neutrophils 1.06 ± 0.09 1.05 ± 0.04 0.99 ± 0.04
Monocytes 1.23 ± 0.21 1.34 ± 0.32 1.29 ± 0.25
LPS-induced cytokines"
(mean ± SE)
IL-Ip 232.3 ± 105.8 250.3 ± 63.9 423.5 ± 113.8
IL-8 96.6 ± 17.8 96.3 ± 29.3 98.8 ± 13.5
TNF-a 1.93 ± 0.2 2.51 ± 1.05 3.36 ± 0.82
"Peak CL values in mV; "Phagocytic index; 'pglmll105 leukocytes.
FMLp, N:formyl-methionyl-Ieucyl-phenylalanine; JL, interleukin; LPS, lipopolysaccharide; PMA, phorbol12-myristate
13-acetate; TNF- a, tumour necrosisJactor- a; WBe, white blood cell
demonstrated by the inhibition of mAb MHM24
binding; nearly complete saturation was obtained
with an efalizumab concentration of I0 ug/rnl, which
is similar to that obtained in vivo at steady-state after
four weekly drug doses (I mg/kg/week).
There were no changes in the binding of the anti-
COila mAb HIIII (Fig. IB) or the anti-CDllb,
CDI28a and CDI28b mAbs (not shown).
Efalizumab had no effect on neutrophil or mono-
cyte chemiluminescence production (spontaneous or
induced by PMA or FMLP) or phagocytic capacity
(Table I), but it did lead to a dose-dependent inhibi-
tion ofneutrophil chemotactic activity in response to
the three chemo-attractants (only a downward trend
in the case ofmonocytes) (Fig. 2A and B).
Ex vivo study
The number ofcirculating neutrophils and mono-
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Fig. 1. Effect of efalizumab in vitro on neutrophil and
monocyte CDlJa binding sites. The cells were pre-incu-
bated with different concentrations of efalizumab before
being stained with thefluorescein i-lsothlocyanate-conju-
gated anti-CD IIa mAb MHM24 (A) or the phycoerythrin-
conjugated anti-CDlla mAb HlllJ (B). The results are
expressed as mean fluorescen ce intensity (MFI) ± stand-
ard error, corrected for non-specific staining from three
separate experiments.
Fig. 2. Effect of efalizumab in vitro on neutrophil and
monocyte chemotaxis. Purified neutrophils (A) and mono-
cytes (B) were pre-incubated with different concentrations
of efalizumab before being assayed for migration versus
three different chemo-attractants: Zymosan-activated
serum (ZAS), N-formyl-methionyl-leucyl-phenylalanine
(FMLP) and interleukin-S (IL-8). The values represent the
mean number ofmigrated cells per high powerfield (hpj)
± standard error from three separate experiments.
*p<O.OJ; **p <O.05 versus medium.
cytes, their functional activities and the membrane
expression of CD11a, CD 11 b, CD 128a and CD128b
were evaluated in blood samples taken from five pa-
tients with severe psoriasis before treatment (TO) and
1 month after the start of therapy with efalizumab
(Tl).
There were no differences in total or differential
leukocyte counts between the patients and controls
at TO but, as expected, mean circulating white blood
cell levels increased by approximately 34% after 1
month of therapy (Table II). Circulating lymphocytes
increased by 60% and circulating neutrophils by
34%; there was no change in the number of mono-
cytes (Table II).
Analysis of neutrophil and monocyte membrane
antigen expression (CD 11 a, CD 11 b, CD 128a and
CD128b) by FACS did not reveal any differences
between patients and controls (Fig. 3A and B for
COlla; not shown for other antigens). After treat-
ment with efalizumab for 4 weeks, the MHM24
mAb showed that the CD 11 a binding sites on both
neutrophils (Fig. 3A) and monocytes (Fig. 3B) were
90% saturated, and the use of the HI III anti-CD 11 a
mAb, which binds to all CD 11 a binding sites regard-
less .of efalizumab binding, showed a significant
decrease in COlla expression (neutrophils 44% of
TO; monocytes 63% of TO) (Fig. 3A and B); there
was no change in the circulating phagocyte mem-
brane expression of CD 11 b, CD 128a or CD128b
(not shown).
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Fig. 3. Effect of efalizumab therapy on CD11a expres-
sion on the membranes of circulating neutrophils (A)
and monocytes (B). Whole blood samples were obtained
from ten controls and five patients with psoriasis before
(TO) and after therapy with efalizumab for 1 month (Tl),
and the neutrophils and monocytes were stained with the
fluorescein 5-isothiocyanate-conjugated anti-CD11a mAb
MHM24 or the phycoerythrin-conjugated anti-CDlla
mAb Hllll. The results are expressed as mean fluores-
cence intensity (MFl) ± standard error, correctedfor non-
specific staining.
*p<O.OOI, Tl versus TO; **p<0.02, Tl versus TO.
Fig. 4. Effect ofefalizumab on neutrophil and monocyte
chemotaxis. Peripheral blood phagocytes were purified
from ten controls and five patients with psoriasis before
(TO) and after therapy with efalizumab for 1 month (Tl).
Mean values ± standard error ofthe number ofmigrated
neutrophils (A) or monocytes (B) per high power field
(hpj) using different chemo-attractants: zymosan-acti-
vated serum (ZAS), N-jormyl-methionyl-Ieucyl-pheny-
lalanine (FMLP) (1(j8 M) and interleukin-8 (IL-8) (100
ng/ml).
*p<O.OOI, Tl versus TO; **p<0.05, Tl versus TO
There was no between-group difference in the ca-
pacity of neutrophils and monocytes to produce re-
active oxygen intermediates, ingest particles (Table
II) or migrate toward a chemo-attractant at TO (Fig.
4). Treatment with efalizumab for 1 month led to no
change in chemiluminescence production or phago-
cytosis (Table 2) but, in line with our in vitro results,
both neutrophil and monocyte chemotactic activity
was significantly inhibited (Fig. 4A and B) in rela-
tion to all three chemo-attractants: respectively, 80%
and 54% inhibition for FMLP, 41% and 57% for IL-
8, and 22% and 43% for ZAS.
Finally, there was no difference in baseline spon-
taneous (not shown) or LPS-induced production of
TNF-a, IL-l~ and IL-8 by leukocytes (Table II) be-
tween patients with psoriasis (TO and Tl) and con-
trols, even if an upward trend for IL-I ~ and TNF-a
production by the patient's leukocytes was observed
at Tl.
DISCUSSION
In the present work we found that a concentra-
tion of efalizumab similar to that obtained in vivo
at therapeutic doses (1-10 ug/ml) (11) almost com-
pletely saturates CD11a receptors on phagocytes
without interfering with the membrane expression
of CDlIb, CDl28a or CD128b. Furthermore, efali-
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zumab caused a dose-dependent inhibition of the
chemotactic capacity of phagocytes toward three
chemo-attractants without modifying phagocytosis
or the production ofROI.
In comparison with control cells, there was no
significant difference in membrane antigen expres-
sion or the functional properties of phagocytes ob-
tained from patients with psoriasis before efalizumab
treatment.
In line with our in vitro results and previous ex
vivo studies (11), treatment with efalizumab for
1 month not only saturated CD 11 a receptors but
also significantly down-modulated their membrane
expression on both neutrophils (44% of TO) and
monocytes (63% of TO). The number of circulating
neutrophils increased by 34% between TO and T1,
but there was no change in the number of mono-
cytes. The almost complete saturation and partial
down-modulation of the COlla binding sites did
not change phagocytosis or phagocyte production of
ROI but, in line with our in vitro results, therapy with
efalizumab significantly inhibited the chemotactic
capacity of both neutrophils and monocytes. This
down-modulation of phagocyte chemotaxis has not
been previously reported for efalizumab in vitro or
ex vivo. Previous studies have shown that impair-
ing LFA-l/ICAM interactions, using monoclonal
antibodies to LFA-l or LFA-l knockout mice, sup-
presses neutrophil and monocyte migration in vari-
ous models of inflammation (22-23); a similar effect
may occur in vivo in patients with psoriasis follow-
ing treatment with efalizumab.
Our in vitro and ex vivo results indicate that the
saturation and/or down-modulation of CD 11 a by
efalizumab inhibits phagocyte migration independ-
ently of the inhibition of LFA-l/ICAM-l interac-
tions. The mechanism underlying this inhibition is
unclear, but seemed to be unrelated to chemotactic
receptor expression as the defect was found with
three different chemo-attractants and there was no
change in membrane CD12SalCXCRI or CDI2Sb/
CXCR2 expression, despite a significant defect in
chemotaxis toward IL-S. The saturation ofCD11 a re-
ceptors by efalizumab may alter the induction of the
migratory phenotype of phagocytes which, among
other things, are characterized by LFA-l redistribu-
tion to their leading edge (24).
There is increasing evidence that T cell dysregu-
lation is involved in the development and mainte-
nance of psoriasis (1-3 ), but the role of neutrophils
and monocytes in its pathogenesis has also been
described: phagocytes are required for the develop-
ment ofpsoriatic plaques and represent an important
pathogenic factor potentiating T cell-associated in-
flammation (12-13, 25-26).
Our data showing that efalizumab saturates
COlla receptors, down-modulates COlla expres-
sion, and significantly inhibits the chemotactic prop-
erties of phagocytes may provide an insight into a
new and efficient mechanism of action by means of
which this biological drug controls plaque psoriasis.
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